Skip to main content
Signal8

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

$BIIBPress releaseJun 4, 2026, 7:30 AM ETRead the release

Biogen announced that the FDA has granted Breakthrough Therapy Designation to salanersen for the treatment of spinal muscular atrophy (SMA). The designation is based on Phase 1b data showing that children with SMA who had suboptimal responses to prior gene therapy experienced slowing of neurodegeneration and clinically meaningful improvements in motor function, including gaining new milestones like sitting and walking. Salanersen is an investigational antisense oligonucleotide with potential for once-yearly dosing, licensed from Ionis Pharmaceuticals.

Key figures

Drug Name
salanersen
Phase Of Trial
Phase 1b
Nfl reduction
75%
Participants treated
24
Dose evaluated phase3
80 mg
Participants new milestones
12

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BIIB: Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy — AI Analysis | Signal8